Literature DB >> 10197608

Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer.

R Roylance1, P Gorman, W Harris, R Liebmann, D Barnes, A Hanby, D Sheer.   

Abstract

How does breast cancer progress? There is evidence both to support (S. W. Duffy et al., Br. J. Cancer, 64: 1133-1138, 1991; R. Rajakariar et al., Br. J. Cancer, 71: 150-154, 1995) and refute (M. Hakama et al., Lancet, 345: 221-224, 1995; R. R. Millis et al., Eur. J. Cancer, 34: 548-553, 1998) the hypothesis of dedifferentiation; the theory that as breast cancers grow they evolve from well differentiated (grade I) to poorly differentiated (grade III) tumors. We provide evidence to support the view that the majority of grade I tumors do not progress to grade III tumors. Comparative genomic hybridization was used to screen entire genomes of a large sample (40 grade I and 50 grade III) of invasive ductal breast carcinomas, stratified by grade. We found distinct genetic differences between grade I and grade III tumors. Significantly, we found that 65% of grade I tumors lost the long arm of chromosome 16 compared with only 16% of grade III tumors. This pattern of loss leads us to conclude that the majority of grade I tumors do not progress to grade III tumors. These findings have important implications because they suggest that different breast tumor grades may have distinct molecular origins, pathogenesis, and behavior and, therefore, potentially present distinct molecular targets for research and treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10197608

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

3.  Breast cancer precursors: lessons learned from molecular genetics.

Authors:  Hans-Peter Sinn
Journal:  J Mol Med (Berl)       Date:  2009-01-13       Impact factor: 4.599

Review 4.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

5.  Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC.

Authors:  O M Sieber; K Heinimann; P Gorman; H Lamlum; M Crabtree; C A Simpson; D Davies; K Neale; S V Hodgson; R R Roylance; R K S Phillips; W F Bodmer; I P M Tomlinson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

Review 6.  Two hits revisited again.

Authors:  I P Tomlinson; R Roylance; R S Houlston
Journal:  J Med Genet       Date:  2001-02       Impact factor: 6.318

7.  Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis.

Authors:  Yutaka Tagawa; Toru Yasutake; Yasushi Ikuta; Tadayuki Oka; Ryusuke Terada
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

8.  Chromosome 1q25.3 copy number alterations in primary breast cancers detected by multiplex ligation-dependent probe amplification and allelic imbalance assays and its comparison with fluorescent in situ hybridization assays.

Authors:  Emilia Wiechec; Jens Overgaard; Eigil Kjeldsen; Lise Lotte Hansen
Journal:  Cell Oncol (Dordr)       Date:  2012-12-18       Impact factor: 6.730

9.  Genomic heterogeneity of breast tumor pathogenesis.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Clin Med Oncol       Date:  2009-07-29

Review 10.  Demystifying basal-like breast carcinomas.

Authors:  L Da Silva; C Clarke; S R Lakhani
Journal:  J Clin Pathol       Date:  2007-05-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.